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This review describes the current state of knowledge of the Raph 
blood group system, which consists of a single antigen, MER2. 
MER2 was initially classified as a high-incidence antigen in the 
901 series of blood groups, formerly known as 901011, but was 
reclassified as an antigen in the Raph blood group system in 
2004. There have been six reports of human alloantibodies to 
MER2. Three of the subjects were found to have a stop codon 
in the CD151 gene, which encodes a member of the tetraspanin 
family of proteins. These three individuals had nephropathy 
and deafness, and two of the three, who are siblings, also had 
skin lesions and β-thalassemia minor. The fourth subject had 
missense mutation c.533G>A (p.Arg178His). Subjects 5 and 6 
shared missense mutation c.511C>T (p.Arg171Cys) as well as a 
synonymous single-nucleotide mutation (c.579A>G) and had no 
clinical features. Although the CD151 protein is critical to cell-
to-cell interactions and cell signaling and is implicated in cancer 
progression, the significance in transfusion medicine is limited 
to one report of a hemolytic transfusion reaction in Subject 5. 
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History
MER2 , the single antigen in the Raph blood group system, 
was first described in 1985.1 The authors described a red blood 
cell (RBC) polymorphism called DEN that subsequently was 
named MER2. MER2 was the first RBC surface antigen to be 
defined by monoclonal antibodies, reacting with monoclonal 
antibodies 2F7 and 1D12.2 The incidence of MER2 in a 
random white population was estimated at 92 percent, with 
approximately 8 percent of individuals showing the Raph-null 
phenotype.2
The first report of human alloantibodies with MER2 
specificity was in 1988 and involved three Jews originating 
in India and living in Israel (Table 1).3 Two were  siblings 
(Subjects 1 and 2) and the third was  unrelated  (Subject 3); 
all possessed the Raph-null phenotype.3,4 A fourth example of 
an antibody with MER2 specificity was described in 2002 in 
a healthy Turkish blood donor (Subject 4).4 In 2008, two more 
examples of anti-MER2 were reported in pregnant women, 
one of Pakistani and the other of Turkish origin (Subjects 5 
and 6, respectively).5
Biochemistry
In 2004, Crew et al.4 demonstrated that MER2 is carried 
on CD151, a member of the cluster of differentiation (CD) 
family. CD proteins are found mostly on leukocytes and are 
often used as laboratory tools to determine developmental 
and functional characteristics of T and B cells.7 Tetraspanins 
(TSPs) span the cell membrane, with two extracellular and two 
intracellular loops and short intracellular, cytoplasmic N- and 
C-termini. The first extracellular loop (EC1) is small, whereas 
the second (EC2) is large. EC2, sometimes characterized as a 
“mushroom head,”8 contains cysteines that form at least two 
conserved disulfide bonds (Fig. 1). CD151 is a TSP with six 
cysteines in EC2 including those in CCG, PXXCC, and GC 
cysteine patterns found in other TSP EC2 domains (Fig. 1).8 
Tetraspanins interact with each other as well as a variety of 
other transmembrane proteins, including integrins. They are 
thought to be involved in cell membrane stability, cell-to-cell 
communication, cell migration, and maintenance of cell-to-
cell contacts.4
Revie w
Table 1. Molecular studies of CD151
Subject number Ethnicity Antigen/ antibody status Nucleotide changes Amino acid changes Allele name Reference
1, 2, 3 Israeli MER2–Anti-MER2 present c.383insG p.Lys127fs + Glu140X RAPH*01N.01 4
4 Turkish MER2–Anti-MER2 present c.533G>A p.Arg178His RAPH*-01.02 4
5 Pakistani MER2–Anti-MER2 present c.511C>T
c.579A>G
p.Arg171Cys RAPH*-01.01 5
6 Turkish MER2–Anti-MER2 present c.511C>T
c.579A>G
p.Arg171Cys RAPH*-01.01 5
7 White MER2–Anti-MER2 present c.494G>A p.Arg165Gln N/A 6
N/A = not available.
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CD151 is the first member of the TSPs to be found on 
RBCs, being present on immature RBCs in the bone marrow. 
As the RBC matures, the amount of CD151 on the cell 
surface decreases.4 MER2 is present on cord cells.7 CD151 
also has been found on epithelium, endothelium, muscle, 
renal glomeruli and proximal and distal tubules, Schwann 
cells, and dendritic cells.9 High levels of CD151 have been 
found on both platelets and megakaryocytes4,10 as well as on 
other cell types.11 CD151 is co-located with integrins α3β1 
and α6β4 in hemi-desmosomes at the basolateral surface of 
basal keratinocytes12 and with α6β4 on endothelial cells.13 
Given the impaired bone marrow responsiveness of CD151-
deficient individuals, this molecule may play an important 
role in erythroid progenitor membrane assembly such that 
the cells are responsive to signals including those via the 
erythropoietin receptor.4
CD151 plays a role in signal transduction. Overexpression 
of CD151 leads to activation of phosphoinositide 3-kinase 
(PI3K), hepatocyte growth factor (HGF), and the c-Met 
signaling pathway. In turn, PI3K upregulates matrix 
metallopeptidase 9 (MMP-9).14 CD151 also regulates RhoA 
and cell-to-cell contacts, and, in doing so, maintains vascular 
stability.15–17 Regulation of cell-to-cell contact through CD151 
involves palmitoylation.18
Genetics and Inheritance
The CD151 gene is 4.3 kilobases in length and located on 
chromosome 11p15.5.2,19,20 The CD151 gene is made up of 8 
exons (Fig. 2) and encodes a 253–amino acid protein product.21 
MER2 is inherited as a Mendelian dominant trait. As a result, 
individuals who express MER2 via one CD151 allele will type 
positive for MER2.7 The reference allele is called RAPH*01 
and encodes a RAPH:1 or MER2+ phenotype.
After the CD151 gene was found to encode the blood group 
antigen MER2, it was reclassified a blood group system by 
the International Society of Blood Transfusion Committee on 
Terminology for Red Cell Surface Antigens19 as described in 
Table 2.22
The CD151 genes of Subjects 1, 2, and 3, all with the 
Raph-null phenotype and anti-MER2 , were subjected to DNA 
sequence analysis.4 Subjects 1 and 2 were homozygous for a 
single-nucleotide insertion in exon 5 (c.383insG). The insertion 
causes a frameshift mutation that leads to a premature stop 
codon at amino acid 140. The resulting truncated protein 
would be predicted to lack a significant part of the second 
large extracellular loop (EC2) and would be unlikely to fold 
properly or reach the plasma membrane.4 Subject 4 was found 
to be homozygous for a nonsynonymous single-nucleotide 
polymorphism (SNP) at nucleotide 533 in exon 6. The 
c.533G>A nucleotide change results in an arginine to histidine 
at amino acid 178 (p.Arg178His) in the EC2 domain. Protein 
modeling did not predict that the amino acid change would 
have a functional effect on the protein.5 Subjects 5 and 6 were 
homozygous for a nonsynonymous SNP in exon 6 at c.511.5 
The nucleotide 511C>T change results in an amino acid change 
of arginine to cysteine at amino acid 171 (p.Arg171Cys). In 
addition, both individuals were homozygous for a synonymous 
Fig. 1 CD151 protein structure shows the protein with its four 
transmembrane domains spanning the cell membrane, including 
the small first extracellular domain (EC1) and the large second 
extracellular domain (EC2). EC2 contains six cysteines (C, black 
circles) in patterns of amino acids found in other TSP family 
members. The gray circles represent noncysteine residues including 
proline (P) and glycine (G). X represents any amino acid.
N-terminus C-terminus
Fig. 2 CD151 gene structure shows the 4.3 kilobases of the gene 
with its 8 exons (boxes). Exonic regions in gray depict the untranslated 
regions whereas those in black depict the coding regions.
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SNP (c.579A>G) in exon 6. Protein modeling of this variant 
suggested that the p.Arg171Cys variant protein would retain 
its integrin-binding capacity but would not have the MER2 
epitope.5 Subject 7 is a white woman negative for MER2 
with anti-MER2 reported to have a CD151 c.494G>A change 
resulting in an amino acid change of arginine to glutamine at 
amino acid 165 (p.Arg165Gln).6
Antibodies
Anti-MER2 is reactive in the antiglobulin phase of 
testing. MER2 is resistant to treatment with sialidase, 
papain, and neuraminidase.7,23 Dithiothreitol (DTT), trypsin, 
chymotrypsin, pronase, and 2-aminoethylisothiouronium 
bromide (AET) denature MER2 by breaking the disulfide 
bonds within EC2.7,24 Blocking studies found that human 
alloanti-MER2 blocked binding of both murine anti-CD151 
and murine anti-MER2 with MER2+ RBCs.4
Alloanti-MER2 has been reported in individuals who do 
not have the antigen expressed on any cell types.4 Most people 
whose RBCs type as MER2– express MER2 on other cell 
types. The presence of CD151 on multiple cell types supports 
early speculation that although 8 percent of the population 
phenotypically types as MER2– on RBCs, they are not at risk 
of alloimmunization to MER2 because of the presence of the 
antigen on other cells.
Clinical Significance
Subjects 1 and 2, who were siblings, as well as Subject 3 
had kidney disease.5 All three subjects with the null mutation 
had nephritic syndrome, which progressed to end-stage renal 
failure requiring dialysis. Subjects 1 and 2 also showed pretibial 
bullous skin lesions, neurosensory deafness, bilateral lacrimal 
duct stenosis, nail dystrophy, and β-thalassemia minor.25 The 
male sibling had a single right kidney and defective teeth, 
and the female sibling had agenesis of the distal vagina and 
bilateral cervical ribs.25
The fourth subject with anti-MER2 was a Turkish blood 
donor (Subject 4).4 This individual had no apparent clinical 
symptoms or abnormalities.
Subjects 5 and 6 were pregnant women; neither was 
reported to have symptoms associated with renal failure.5 
Subject 5 experienced a hemolytic transfusion reaction after 
transfusion of three units of RBCs. A monocyte monolayer 
assay suggested the antibody could be clinically significant, 
and the patient’s serum contained no other alloantibodies.5
MER2 may be associated with other disease states. CD151 
has been linked to modulation of platelet function.26 CD151-
null mice show increased bleeding time and decreased clotting 
ability.27 Intravital microscopy in mice with and without 
CD151 expression demonstrated that the protein is required 
for regulating thrombus formation in vivo.9 In addition, there 
is a growing body of evidence suggesting that increased 
expression of CD151 is associated with poor prognosis in a 
variety of cancers.28–32
Weakened or reduced expression of MER2 on RBCs has 
been associated with the inheritance of In(Lu).7 The In(Lu) 
phenotype is caused by a mutation in the promoter of EKLF 
(KLF1),33 a transcription factor that is required for expression 
of Lutheran and other blood group antigens. Although 
regulation of CD151 is not well understood,34 if EKLF plays 
a role in its expression, this is consistent with the finding of 
weakened MER2 expression on RBCs of the In(Lu) phenotype.
Mice lacking CD151 show abnormal basement membrane 
biosynthesis and maturation, maintenance, and function of 
the kidney filter.35 Thus, animal modeling and the clinical 
presentation of Subjects 1, 2, and 3 suggest a link between 
Raph and the basement membrane of the kidney, skin, inner 
ear, and other tissues. Mice lacking CD151 also demonstrate 
abnormal wound healing.36
Conclusions
The Raph blood group system is currently made up of a 
sole antigen, MER2, encoded by CD151. MER2 is expressed 
on RBCs as well as other cell types. CD151 has been associated 
with kidney function, cell-to-cell interactions, platelet function, 
and cancer progression. Evidence suggests that MER2– 
individuals express MER2 on other cell types.4 This would be 
similar to Fyb in the Duffy system, in which the FYB allele can 
be silenced in RBCs based on the presence of an SNP in the 
promoter region, while being expressed in other tissues.37
The clinical significance of anti-MER2 in RBC transfusion 
is not clear. Additional examples of the antibody will need to 
be studied to determine the impact on RBC survival. Given 
that approximately 8 percent of whites are MER2–, it should 
be possible to crossmatch such individuals.
M. Hayes
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